Hydrochlorothiazide Does Not Affect Recurrence of Kidney Stones
FRIDAY, March 10, 2023 -- Hydrochlorothiazide does not reduce the risk for recurrence among patients with recurrent kidney stones, according to a study published in the March 2 issue of the New England Journal of Medicine.
Nasser A. Dhayat, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2023 Category: Pharmaceuticals Source Type: news
Occurrence of Cardiovascular Events, Death Compared Between Thiazides
TUESDAY, Jan. 3, 2023 -- For patients receiving thiazide diuretics, the occurrence of major cardiovascular outcome events or non-cancer-related deaths is no lower for those receiving chlorthalidone versus those receiving hydrochlorothiazide,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2023 Category: Pharmaceuticals Source Type: news
Chlorthalidone, HCTZ Equally Effective: DCP Published Chlorthalidone, HCTZ Equally Effective: DCP Published
The Diuretic Comparison Project trial, showing no difference in clinical events between diuretics chlorthalidone and hydrochlorothiazide for hypertension, is now published in NEJM.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - December 15, 2022 Category: Primary Care Tags: Cardiology News Source Type: news
Meds and Community Over Mindfulness for Most Hypertension Meds and Community Over Mindfulness for Most Hypertension
Catch up on blood pressure presentations from the 2022 American Heart Association meeting, including ones on mindfulness, community approaches, and a comparison of hydrochlorothiazide and chlorthalidone.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 11, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Diuretics on Par in Head-to-Head Comparison for Hypertension
(MedPage Today) -- Chlorthalidone didn't best hydrochlorothiazide (HCTZ) for reducing cardiovascular risk in the treatment of hypertension, a pragmatic VA trial showed.
For the primary outcome of major adverse cardiovascular events and non-cancer... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 6, 2022 Category: Urology & Nephrology Source Type: news
HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science
In the Diuretic Comparison Project, hydrochlorothiazide held its own compared with chlorthalidone as first-line hypertension agent despite U.S. experts ' preference for the latter -- a lesson for us all, writes John Mandrola, MD.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 5, 2022 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP Diuretic Agents Equal to Prevent CV Events in Hypertension: DCP
The Diuretic Comparison Project randomized trial showed almost identical rates of the primary composite cardiovascular endpoint between the commonly used diuretics chlorthalidone and hydrochlorothiazide.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 5, 2022 Category: Internal Medicine Tags: Cardiology News Source Type: news
Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Recall of Two (2) Lots of Quinapril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, Due to the Detection of N-Nitroso Quinapril Impurity
East Windsor, New Jersey, Aurobindo Pharma USA, Inc. has initiated a voluntary recall of two (2) lots (refer table below) of Quinapril and Hydrochlorothiazide Tablets USP 20mg / 12.5mg, to the consumer level from the US market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 25, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Moduretic (Amiloride and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 6, 2022 Category: Drugs & Pharmacology Source Type: news
Pfizer Voluntary Nationwide Recall of Lots of Accuretic (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-Nitroso-Quinapril Content
Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient(consumer/user) level due to the presence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 5, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pfizer Voluntary Nationwide Recall of Lots of ACCURETICTM (Quinapril HCl/Hydrochlorothiazide), Quinapril and Hydrochlorothiazide Tablets, and Quinapril HCl/Hydrochlorothiazide Tablets Due to N-NitrosoQuinapril Content
Pfizer is voluntarily recalling Accuretic (quinapril HCl/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril and hydrochlorothiazide and quinapril HCl/ hydrochlorothiazide) to the patient(consumer/user) level due to the presence (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 22, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Benicar HCT (olmesartan medoxomil-hydrochlorothiazide)
Title: Benicar HCT (olmesartan medoxomil-hydrochlorothiazide)Category: MedicationsCreated: 11/8/2021 12:00:00 AMLast Editorial Review: 11/8/2021 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - November 8, 2021 Category: Cardiology Source Type: news
Capozide (Captopril and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Apresazide (Hydralazine and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 29, 2021 Category: Drugs & Pharmacology Source Type: news
